Sun On Leqselvi US Launch Ahead, MFN Pricing And Pipeline Changes

Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.

Strategy — Sun readies at-risk launch (Shutterstock/AI-generated)

Sun signaled launch action ahead in the US and a change in plan for certain pipeline specialty assets, even as it awaits, like other industry peers, more clarity on details around US President Donald Trump’s “most favored nation” prescription drug pricing plan (see box below).